Non Alcoholic Steatohepatitis is an emerging disease with high prevalence in the world population !
In the coming years, the treatment of the disease will become a big challenge and a huge market .
Many laboratories are developing compounds targeting NASH and are working hard to lead the race.
We developed a database including the compounds, their targets, and computed a model tempting to predict the future NASH market landscape.
This publication reflects the views only of the authors, and he cannot be held responsible for any use which may be made of the information contained therein. The authors of the articles published here are not physician, financial analysts or market professionals. announced data may contain errors, inaccuracies and misinterpretations of facts.The authors could have their own stoks positions on these values. it is therefore recommended to the reader to verify the facts, to inform himself before any investment on listed companies and to make decisions based on his own judgment. The informations and reflections that can be found on this website are by no means of incentives for the purchase or sale of listed securities but personal opinions of the authors, which does not represent the point of view of the mentionned companies .
Positions of G.Divry on the biotech’s mentioned :
GENFIT : H1 2013 - to date: Long
CONATUS : to date: No Position
GALT : Jan 2018 - to date: Long
MDGL : to date : No Position
ICPT : to date : No Position